Lv534
890 积分 2024-03-06 加入
Recent advances in therapeutic targeting of the KRAS pathway in cancer
29天前
已完结
USP1 inhibition: A journey from target discovery to clinical translation
1个月前
已完结
The new normal: immunomodulatory agents against sepsis immune suppression
1个月前
已完结
Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer
1个月前
已完结
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
2个月前
已完结
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
2个月前
已完结
Cancer mRNA vaccines: clinical advances and future opportunities
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Clinical advances of mRNA vaccines for cancer immunotherapy
2个月前
已完结
皖公网安备34019202002308
